Sun Pharmaceutical, which is purchasing Ranbaxy Laboratories from Daiichi Sankyo for $4 billion, is said to be planning to capitalize on its alliance with the company to introduce its generic drugs to the Japanese market three to four years after the Ranbaxy deal closes. The Japanese government has said it intends to increase market share of generic drugs in the country to 60% by 2017.

Related Summaries